<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01634373</url>
  </required_header>
  <id_info>
    <org_study_id>PK-08-111</org_study_id>
    <nct_id>NCT01634373</nct_id>
  </id_info>
  <brief_title>Steady State Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets</brief_title>
  <official_title>An Open-Label, Randomised, 2-Period, 2-Treatment, 2-sequence, Crossover, Steady State Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets [Test Formulation; Torrent Pharmaceuticals Ltd., India] Versus SeroquelÂ® 300 mg Tablet [Reference Formulation; AstraZeneca, USA] in Schizophrenic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective:&#xD;
&#xD;
      Primary objective was to study Steady-state bioequivalence of Torrent's Quetiapine Fumarate&#xD;
      Tablets 300 mg.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      Randomized, Two-Way, Crossover, multiple Dose, and Open-Label&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Schizophrenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Torrent's Quetiapine Fumarate Tablets</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sex: Male of female&#xD;
&#xD;
          -  Age: 25-65 years&#xD;
&#xD;
          -  Patients who are receiving a stable daily dose of quetiapine 300 mg every 12 hourly&#xD;
             for atlist one month&#xD;
&#xD;
          -  Patient willing to adhere to the protocol requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically relevant abnormalities in the results of the laboratory screening&#xD;
             evaluation.&#xD;
&#xD;
          -  Clinically significant abnormal ECG.&#xD;
&#xD;
          -  Significant orthostatic hypotension (i.e., a drop in systolic blood pressure of 30 mm&#xD;
             Hg or more and/or a drop in diastolic blood pressure of 20 mm Hg or more on standing)&#xD;
&#xD;
          -  Concurrent use of antihypertensive medication or any medication that might pre-dispose&#xD;
             to orthostatic hypotension.&#xD;
&#xD;
          -  History of allergic reactions to quetiapine or other chemically related psychotropic&#xD;
             drugs.&#xD;
&#xD;
          -  Concurrent primary psychiatric or neurological diagnosis including organic mental&#xD;
             disorder, severe tardive dyskinesia, or idiopathic Parkinson's disease.&#xD;
&#xD;
          -  Existence of any surgical or medical condition, which in the judgement of the&#xD;
             Principal Investigator, might interfere with the absorption, distribution, metabolism&#xD;
             or excretion of the drug or likely to compromise the safety of patients.&#xD;
&#xD;
          -  Concurrent use of other drugs known to suppress bone marrow function.&#xD;
&#xD;
          -  HIV, HCV, HBsAg positive.&#xD;
&#xD;
          -  Expected changes in concomitant medications during the period of study.&#xD;
&#xD;
          -  A history of epilepsy or risk for seizures&#xD;
&#xD;
          -  positive urine drug of abuse test at enrollment.&#xD;
&#xD;
          -  A history of alcohol or drug dependence by Diagnostic and statistical manual of Mental&#xD;
             disorders IV(DSM-IV) criteria during the 6 month period immediately prior to study&#xD;
             entry.&#xD;
&#xD;
          -  A total white blood cell count below 4000/ml, or absolute neutrophil count below&#xD;
             2000/ml&#xD;
&#xD;
          -  Female patients with pregnancy or Breast feeding or intend to become pregnant during&#xD;
             the study and not able to follow contraception methods.&#xD;
&#xD;
          -  History of multiple syncopal episodes.&#xD;
&#xD;
          -  Administration any study drugs in last 3 months prior to entry in the study.&#xD;
&#xD;
          -  History of significant blood loss due to any reason in the past 3 months.&#xD;
&#xD;
          -  Any pre-existing bleeding disorder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asha Hospital</name>
      <address>
        <city>Hyderabad</city>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>June 27, 2012</study_first_submitted>
  <study_first_submitted_qc>July 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2012</study_first_posted>
  <last_update_submitted>July 2, 2012</last_update_submitted>
  <last_update_submitted_qc>July 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

